Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer
Maria Vittoria Dieci(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Federica Miglietta(University of Padua), Roberto D’Amico(University of Modena and Reggio Emilia), Melinda E. Sanders(Vanderbilt University), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Stefania Bartolini(Istituto delle Scienze Neurologiche di Bologna), Alessio Schirone, Sara Balduzzi(Dutch Cancer Society), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Enrico Orvieto(AULSS 2 Marca Trevigiana), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Elena Bertone, PierFranco Conte(University of Padua), Davide Massa(University of Padua)
Cited by 17
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830